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high iron requirements such as those observed during pregnancy or
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with menorrhagia.1
Treatment includes controlling the bleeding and replenishing lost
iron. Oral iron remains the front-line standard primarily because of its
convenience and low cost. However, international guidelines recommend intravenous (IV) iron as the preferred route when there is intoler-
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need.2–4
Iron isomaltoside is one of the newer IV iron formulations able to
supply a complete replacement dose in a short, single visit in most
Herein, we present data from a subpopulation of gynecology
patients with IDA from a previously reported trial.5 The objective was
in gynecology patients (corresponding to 48.5% of those in the larger
trial) with IDA and who were intolerant of, or unresponsive to oral iron
therapy or who would benefit from rapid iron repletion.
Patients were randomized 2:1 to iron isomaltoside (Monofer®,
Pharmacosmos A/S, Holbaek, Denmark) or iron sucrose (Venofer®,
Vifor Pharma, Glattbrugg, Switzerland).5
The primary efficacy endpoint was the proportion of patients with
a hemoglobin (Hb) increase of 2 g/dL from baseline (ie, dosing) at any
time from week 1 to 5. Secondary efficacy endpoints were time to Hb
increase 2 g/dL, and change in Hb, s-ferritin, transferrin saturation
(TSAT), and total quality of life (QoL) score (Short Form 36 [SF-36]
questionnaire). Safety endpoints included the number of patients who
experienced any adverse drug reaction (ADR). The primary endpoint
was tested for non-inferiority. If the 95% confidence interval (CI) was
above 0, this was evidence of superiority in terms of statistical significance at the 5% level. Remaining endpoints were only tested for
superiority.
Two hundred forty-eight patients were randomized to either
the iron isomaltoside (164) or iron sucrose group (84). Baseline
characteristics were comparable between the treatment groups.
The mean cumulative dose of iron isomaltoside was 1687 (SD: 381)
mg and of iron sucrose 1154 (SD: 368) mg. The difference in cumu-
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lative doses is reflective of the ability to administer a larger dose of
iron isomaltoside in a single setting resulting in fewer administrations and a shorter treatment period to reach the desired iron
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dose.
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from week 1 to week 5 (mean [SD]) was 2.83 (1.33) g/dL in the iron

Iron deficiency anemia (IDA) is highly prevalent in women. The main

isomaltoside group and 2.34 (1.22) g/dL in the iron sucrose group.

risk factors for IDA include a low intake of iron, poor absorption, and

Increases in Hb in the PP analysis set were consistent with superiority

The primary analysis was conducted on both the full analysis set
(FAS) (N 5 237) and the per protocol (PP) analysis set (N 5 223).
There were more responders in the iron isomaltoside group compared to the iron sucrose group. A risk difference of 13.9%-points in
the FAS and 14.3%-points in the PP set as well as non-inferiority of
iron isomaltoside to iron sucrose was observed.
A predetermined test for superiority was performed, confirming superiority of iron isomaltoside over iron sucrose (FAS: P 5 .033; PP: P 5 .031).
In the FAS, the largest increase in Hb from baseline to any time
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of iron isomaltoside over iron sucrose (2.88 [1.30] vs. 2.39 [1.20] g/dL).
For both FAS and PP, the difference between iron isomaltoside and
iron sucrose was statistically significant (P < .001).
Analysis of time to Hb increase 2 g/dL showed a statistically significantly shorter time to Hb increase 2 g/dL in the iron isomaltoside
group compared with the iron sucrose group with a hazard ratio (HR)
(95% CI) of 1.71 (0.19; 0.89) (P 5 .0026).
The change from baseline in Hb and TSAT was statistically significantly higher in the iron isomaltoside compared to the iron sucrose
group at each time point (P  .0005 and P  .0001, respectively)
(Figure 1), and s-ferritin was statistically significantly higher with iron
isomaltoside at weeks 1 to 4 (P  .002) (Figure 1).
In both treatment groups, the SF-36 scores in the eight health
domains improved from baseline to weeks 2 and 5. There were no differences between the groups.
The ADR profiles in the treatment groups were similar to the ones
observed in the main trial.5
One (0.6%) in the iron isomaltoside group experienced serious
ADRs (serious adverse reactions [SARs]; dyspnea and pruritic rash) for
which the patient was admitted to the hospital. On the day after
receiving iron isomaltoside, the subject experienced pruritic rash. There
was no involvement of mucous membranes or fever. The event had a
duration of 11 days and the patient made full recovery. No SAR was
observed in the iron sucrose group.
In this trial, we evaluated the efficacy and safety of IV iron isomaltoside in comparison to iron sucrose in gynecological patients with
IDA. The women were primarily pre-menopausal with a history of menorrhagia but were otherwise healthy.

F I G U R E 1 Change in hemoglobin, s-ferritin, and transferrin saturation
over time by treatment group, full analysis set. CI: confidence interval

For the primary endpoint, the proportion reaching a Hb increase
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non-inferiority and superiority was confirmed for iron isomaltoside
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compared to iron sucrose. Furthermore, a significantly shorter time to
Hb increase 2 g/dL was observed with iron isomaltoside. For all biochemical efficacy parameters (Hb, s-ferritin, and TSAT) measured, more
rapid and/or greater improvements were found with iron isomaltoside.
These findings are in agreement with results of the main trial.5
QoL improved in both treatment groups during the trial. In a previous trial including women with postpartum hemorrhage, a single dose of
iron isomaltoside led to statistically significant differences in fatigue and
depression scores, as well as in hematological and iron parameters, all
favoring iron isomaltoside when compared with standard medical care.6
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related donors.4 The use of post-transplant high dose cyclophosphamide to eradicate allo-reactive T cells and reduce graft-versus-host disease has expanded the donor pool.
The majority of SCD patients are managed outside a comprehensive sickle cell program, in the real world. The applicability of and bar-

Funding information

riers preventing allogeneic HPCT from being offered to these SCD

Pharmacosmos A/S

patients remain to be determined. We, therefore, carried out a survey
of a random cohort of adult patients who received their care at a medical center that does not have a dedicated sickle cell program.

R E FER E NCE S
[1] WHO Global database on anaemia, Center for Disease Control and
Prevention. Worldwide Prevalence of Anaemia 1993–2005. Spain:
World Health Organization; 2008. Available at: http://apps.who.int/
iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsession
id5=DE0809C8C8FB930B8F4B38088937C629?sequence5=1
[2] Dignass AU, Gasche C, Bettenworth D, et al. European consensus on
the diagnosis and management of iron deficiency and anaemia in
inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–222.
[3] KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease, 2012, Vol.2. http://www.kdigo.org/clinical_practice_guidelines/
pdf/KDIGO-Anemia%20GL.pdf. Accessed December 21, 2017.
[4] Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and
management of iron deficiency and anemia in inflammatory bowel
diseases. Inflamm Bowel Dis. 2007;13(12):1545–1553.

A total of 99 adult patients were identified. The distribution of the
SCD was: 75 HbSS, 19 HbSC, and 5 unknown. There were 49 males
and 50 females. Median age was 26 years (range 17–65). Forty-two
(42.4%) of these patients received hydroxyurea. To determine how
many SCD patients would be eligible for allogeneic HPCT, we first
used the five SCD-related medical indications adopted for three multicenter studies (Clinicaltrials.gov Identifiers: NCT01565616, NCT02766465,
and NCT03263559). These criteria, in addition to a diagnosis of SCD,
were as follows: A history of stroke, at least two acute chest syndromes
within two years, multiple hospitalization for painful crisis (>3 a year for
two years), blood transfusion need of >8 units a year, and presence of
pulmonary hypertension. The proportion of patients who were eligible
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for allogeneic HPCT based on these indications was 54.5% (95%
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been included in many single-center studies: A history of multiple priap-

confidence interval (CI): 44.75-64). This proportion increased to 58.6%
(95% CI: 48.7–67.8) when we included two more criteria that have also
ism and multiple osteonecrosis. These data, therefore, indicate that a
large proportion of adult SCD patients treated in the real world could
potentially be candidates for allogeneic HPCT. By far, the SCD-related
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criteria most commonly met for these studies were multiple hospital
admissions for painful crisis and high blood transfusion requirements, fol-
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lowed by pulmonary hypertension, multiple osteonecrosis, and stroke

Applicability of and potential
barriers preventing allogeneic
stem cell transplant in sickle
cell patients treated outside a
sickle cell program

in patients with frequent pain crises and end-organ damage.
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bidity index (HCT-CI)5 to estimate the 2-year transplant-related mortal-

Despite improvement in the life-expectancy of children with sickle cell

ity in these patients if they were to undergo allogeneic HPCT. The 2-

disease (SCD), there has been little change in the mortality rate among

year transplant-related mortality estimated by HCT-CI has been

(Figure 1A). A previous study found that mortality among adult SCD
patients was higher in those with >4 pain crises a year or a high organ
severity score,1 arguing for the utilization of allogeneic HPCT, particularly,
Patients with high SCD-related comorbidities are more susceptible
to transplant-related mortality after allogeneic HPCT. To determine the
impact of SCD-related comorbidities on the applicability of allogeneic
HPCT, we used the hematopoietic cell transplantation-specific comor-

Cardiopulmonary complica-

adjusted for age and transplant preparative regimen. A correlation was

tions remain the major causes of death in these patients. Although

observed between the number of SCD-related comorbidities and the

hydroxyurea reduces the acute sickle-related events, it does not appear

HCT-CI scores (R 5 0.3; 95% CI: 0.04-0.52) (P 5 .024) (Figure 1B). This

to protect against the cardiopulmonary complications.3 Whether newer

correlation persisted even when recurrent priapism and multiple osteo-

agents such as crizanlizumab and L-glutamine change the outcome of

necrosis were added to the five SCD-related complications used in the

the disease remain to be determined.

multicenter studies (data not shown).

1,2

adult patients in the last few decades.

Allogeneic hematopoietic progenitor cell transplant (HPCT) is cur-

Based on the HCT-CI scores, these patients were divided into low-

rently the only cure available to patients with SCD. However, its applic-

risk, intermediate-risk, and high-risk groups. Less than half of the

ability was limited by the lack of related human leukocyte antigen

patients (41.4%; 95% CI: 29.6–54.2) belonged to the low-risk, 24%

(HLA)-matched donors. Only 18% of SCD patients have HLA-identical

(95% CI: 15–36.5) intermediate-risk, and 34.5% (95% CI: 23.6–47.3)

